TY - JOUR
AU - 
AB - ORIGINAL RESEARCH ARTICLE published: 09 April 2014 doi: 10.3389/fonc.2014.00075 Targeted disruption of the JAK2/STAT3 pathway in combination with systemic administration of paclitaxel inhibits the priming of ovarian cancer stem cells leading to a reduced tumor burden 1,2 3 1 1,4 1,4 Khalid Abubaker , Rodney B. Luwor , Ruth Escalona , Orla McNally , Michael A. Quinn , 2,5 1,4,6 1,2,4,6 Erik W.Thompson , Jock K. Findlay and Nuzhat Ahmed * Women’s Cancer Research Centre, Royal Women’s Hospital, Parkville, VIC, Australia Department of Surgery, St Vincent Hospital, University of Melbourne, Melbourne, VIC, Australia Department of Surgery, Royal Melbourne Hospital, University of Melbourne, Melbourne, VIC, Australia Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, VIC, Australia St Vincent’s Institute, Fitzroy, VIC, Australia Prince Henry’s Institute of Medical Research, Clayton, VIC, Australia Edited by: Chemotherapy resistance associated with recurrent disease is the major cause of poor Viive Maarika Howell, University of survival of ovarian cancer patients. We have recently demonstrated activation of the Sydney, Australia JAK2/STAT3 pathway and the enhancement of a cancer stem cell (CSC)-like phenotype Reviewed by: in ovarian cancer cells treated in vitro with chemotherapeutic agents. To elucidate further Viive Maarika Howell, University of these mechanisms in 
TI - Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden
JF - Frontiers in Oncology
DO - 10.3389/fonc.2014.00075
DA - 2014-04-09
UR - https://www.deepdyve.com/lp/unpaywall/targeted-disruption-of-the-jak2-stat3-pathway-in-combination-with-MTC8XdAYB5
DP - DeepDyve
ER -